Business

BofA slashes Doximity price target to $38 amid downgrade wave

By Peace Longe TheStreet

Updated May 17, 2026 5:22 PM

Doximity (DOCS) investors are watching one of the steepest sell-side resets the stock has seen in years.

In the 24 hours after Doximity released its fiscal fourth-quarter results and fiscal 2027 outlook on May 13, more than 10 Wall Street firms either downgraded the stock, slashed their price targets, or both.

Shares fell roughly 24% on May 14, according to Benzinga, and are now down more than 45% year to date.

BofA Securities became the latest firm to weigh in. Analyst Allen Lutz cut his price target on Doximity to $38 from $47 while keeping a buy rating, Investing.com confirmed.

That marks the third time in less than five months that BofA has trimmed its outlook on the digital health platform for physicians.

The story here is not just a single price target cut. It is a coordinated reset of expectations across nearly every bank that covers the name, and a sharp rethink of how quickly Doximity can monetize its push into clinical AI.

For investors holding the stock or considering buying the dip, the question is whether the new, lower bar finally reflects reality or whether it still has further to fall.

BofA cuts Doximity price target: what actually changed

BofA kept its buy rating intact, but the price cut signals real concern.

Lutz now values Doximity at roughly 20 times calendar 2026 EV/EBITDA, down from about 22 times, Investing.com indicated.

EV/EBITDA is enterprise value divided by earnings before interest, taxes, depreciation, and amortization, and it tells you what investors are paying for each dollar of operating cash earnings.

The analyst flagged "less visibility into growth and elevated execution risk" as the reason for the cut.

He also noted that Doximity now trades at just 8 times EBITDA, which works out to a 12% free cash flow yield on fiscal 2027 numbers.

In plain terms, the market is pricing the stock as if growth has effectively ended.

BofA does not believe that, but the firm is acknowledging the bull case will take longer to play out than it previously thought. That hedged framing echoes how BofA recently approached Palantir after earnings, trimming expectations without abandoning its thesis.

BofA's latest price target cut adds to a broader Wall Street reset on Doximity stock.

Photo by Anna Moneymaker on Getty Images

The fiscal 2027 guidance that triggered the downgrade wave

The selloff started on the evening of May 13, when Doximity reported fiscal Q4 2026 results and gave fiscal 2027 guidance that came in well below Wall Street's expectations.

Revenue for the quarter was $145.4 million, up 5% year over year and slightly above the $144 million consensus.

But the forward outlook is what spooked the Street. Doximity guided full-year fiscal 2027 revenue to $664 million to $676 million, according to Investing.com, implying roughly 3% to 5% growth, against Street expectations near $697 million.

Adjusted earnings per share of $0.26 also missed the $0.28 consensus and dropped sharply from $0.38 in the year-ago quarter.

On the earnings call, management called fiscal 2027 an "AI investment year." Doximity is plowing money into compute costs, its DoxGPT clinical AI tool, and brand marketing, before any of that spending begins to generate material revenue.

CEO Jeff Tangney did highlight one bright spot: Doximity posted record free cash flow of $107 million in the quarter, its first-ever nine-digit free cash flow quarter.

Analyst price target cuts on DOCS over the past 72 hours

Here is how the downgrade wave shook out:

BofA: Maintained buy, target cut from $47 to $38
Jefferies: Downgraded to hold from buy, target cut from $51 to $19
Wells Fargo: Downgraded to equal weight from overweight, target cut from $32 to $18
Baird: Downgraded to neutral from outperform, target cut from $40 to $18
KeyBanc: Downgraded to sector weight from overweight
BTIG: Downgraded to neutral from buy
Morgan Stanley: Maintained overweight, target cut from $49 to $35
Needham: Maintained buy, target cut from $55 to $27
Raymond James, Mizuho, BMO, Truist, Evercore ISI: All cut targets

Sources: MoneyCheck, GuruFocus, Investing.com, Sahm

That is a near-unanimous reset, and the kind of coordinated move that tends to weigh on a stock for several quarters before sentiment turns.

Goldman Sachs has used similar language to caution investors during analyst resets, including in its recent message on Google and Amazon earnings expectations.

Why the AI investment story is suddenly a problem

Investors loved the AI angle when Doximity first introduced DoxGPT. It is essentially a HIPAA-aware AI assistant that helps physicians draft notes, summarize records, and search clinical content.

The promise was that Doximity could become the default AI workflow tool for U.S. doctors, given it already reaches more than 85% of them.

More BofA:

Now that story is colliding with two harder realities.

First, AI compute is expensive, and Doximity is absorbing those costs before the revenue arrives. That mirrors the broader AI infrastructure spending cycle hitting most software platforms right now.

Second, a privately-held competitor called OpenEvidence has become a serious challenger in clinical AI search, Business Insider notes, raising real questions about whether Doximity's lead is as defensible as investors assumed.

KeyBanc explicitly cited the rise of "AI-driven and lower-cost alternatives" when it downgraded the stock.

How pharma ad weakness ties into broader health care ad slowdown

Doximity makes most of its money selling targeted ads to pharmaceutical companies that want to reach physicians.

Management acknowledged on the call that "short-term demand in the HCP digital pharma ad market is soft," and that they expect overall market growth at or below 5%.

This is not just a Doximity problem. Pharma marketing peer OptimizeRx flagged similar pharma budget strains ahead of Doximity's report, Investing.com confirmed.

For sectors tied to pharma marketing spend, that is a cautionary signal worth watching.

What needs to happen for Doximity stock to recover

A few specific catalysts could change the narrative:

Stable pharma ad budgets may emerge in the back half of fiscal 2027, especially in the high-margin point-of-care module.
Early revenue traction from DoxGPT and PeerCheck, even a modest contribution, would reset the AI thesis.
Stable market share could exist in the face of OpenEvidence, ideally backed by visible enterprise wins.
Disciplined buybacks may unfold without overpaying, as the company repurchased $432 million of stock in fiscal 2026, The Globe and Mail reported.

Until at least two of these show up in quarterly results, the stock is likely to trade as a "show me" story.

The bottom line for DOCS investors

Doximity is now trading like a business in structural decline, but the underlying numbers do not fully support that view. Revenue still grew, free cash flow hit a record, and gross margins remain near 90%.

The risk is not whether Doximity is a real business. It clearly is.

The risk is time, and specifically, how many quarters of soft growth investors are willing to sit through before AI monetization shows up. That is the same patience question facing investors in other AI-exposed names this year, including Apple after its own analyst reset.

For long-term investors, the BofA call is a reasonable middle-ground view: the business is intact, the multiple is finally reasonable, and the bull case still exists, just on a longer runway.

For shorter-term investors, the absence of near-term catalysts and the depth of the downgrade wave argue for patience before stepping in.

Either way, the next two quarterly reports will tell you whether fiscal 2027 is really just a transition year, or the start of something harder to fix.

The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.

This story was originally published May 17, 2026 at 5:07 PM.